达安基因间接控股股东拟变更为广药集团

Core Viewpoint - The acquisition framework agreement between Guangzhou Jin Kong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group regarding the control of Da An Gene is a significant development, indicating a potential shift in ownership dynamics while maintaining the current controlling structure under the Guangzhou Municipal Government [1][2]. Group 1: Acquisition Details - Guangzhou Pharmaceutical Group intends to acquire 100% equity of Guang Yong Technology held by Guangzhou Jin Kong Group, indirectly controlling 233 million shares of Da An Gene [1]. - The agreement includes the transfer of approximately 70.17 million shares each from Guangzhou Jin Kong Group and Guangzhou Health Industry Investment, totaling around 140.34 million shares [1]. - Post-transaction, Guangzhou Pharmaceutical Group will control approximately 374 million shares, representing 26.63% of Da An Gene's total equity, while Guangzhou Jin Kong Group will retain 5% through Guangzhou Health Industry Investment [1][2]. Group 2: Financial Implications - The share transfer price is set at 6.47 yuan per share, amounting to a total consideration of approximately 908 million yuan [2]. - Da An Gene reported a revenue of 503.5 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 14.81%, with a net loss of 141.5 million yuan, an increase in loss of 71.85% compared to the previous year [3]. Group 3: Market Position - As of November 17, Da An Gene's stock price was 6.9 yuan per share, with a total market capitalization of 9.684 billion yuan [4].